Biomarkers for ovarian cancer detection and therapy

Cancer Biology and Therapy

Volumn 9, Issue 9, 2010, Pages 668-677

  Dutta, Sonia ^a   Wang, Feng Qiang ^a   Phalen, Adrien ^a   Fishman, David A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Contrast enhanced ultrasound; Early detection; Epithelial ovarian cancer; Proteomics; Serum biomarkers; Signaling pathways

Indexed keywords

ACID PROTEIN; ASPARTATE AMMONIA LIGASE; BEVACIZUMAB; BIOLOGICAL MARKER; BRCA1 PROTEIN; CA 125 ANTIGEN; CEDIRANIB; CISPLATIN; CLAUDIN; ENTACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FOLATE RECEPTOR; FOLATE RECEPTOR ALPHA; HISTONE; HUMAN EPIDIDYMAL PROTEIN E4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KALLIKREIN; LYSOPHOSPHATIDIC ACID; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN; NIDOGEN 2; OSTEOPONTIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; TUMOR MARKER; AFLIBERCEPT; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CA 72-4 ANTIGEN; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; FOLATE RECEPTOR 1; GEFITINIB; GEMCITABINE; I KAPPA B; TAXANE DERIVATIVE;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER THERAPY; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; EPIGENETICS; HUMAN; METASTASIS; OVARY CANCER; PROTEIN MODIFICATION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TRANSVAGINAL ECHOGRAPHY; FEMALE; METABOLISM; OVARY TUMOR; PROGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; EARLY DIAGNOSIS; HISTONE MODIFICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIC EXAMINATION; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952023579     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.9.11610     Document Type: Review

References (115)

1. Jemal A, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49.
2. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 1968; 65:281-393.
3. Rockhill B. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002; 360:169. (Pubitemid 34786212)
4. th ed. Philadelphia: Lippincott Williams & Wilkins 2005; 1419.
5. Grover SR, Quinn MA. Is there any value in bimanual pelvic examination as a screening test. Med J Aust 1995; 162:408-10.
6. Skates SJ, et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 2004; 22:4059-66.
7. Giuntoli RL, 2nd, et al. Mucin gene expression in ovarian cancers. Cancer Res 1998; 58:5546-50.
8. Singh AP, et al. Clinical potential of mucins in diagnosis, prognosis and therapy of ovarian cancer. Lancet Oncol 2008; 9:1076-85.
9. Xu Y, et al. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 1995; 309:933-40.
10. Xu Y, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995; 1:1223-32.
11. Eder AM, et al. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res 2000; 6:2482-91.
12. Murph MM, et al. Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation. Biochim Biophys Acta 2008; 1781:547-57.
13. Chun J, et al. International Union of Pharmacology XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 2002; 54:265-9.
14. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3:582-91.
15. Murph MM, et al. Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One 2009; 4:5583.
16. Xu Y, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280:719-23. (Pubitemid 28405297)
17. Meleh M, et al. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 858:287-91.
18. Sedlakova I, et al. Lysophosphatidic acid: an ovarian cancer marker. Eur J Gynaecol Oncol 2008; 29:511-4.
19. Moore RG, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008; 108:402-8.
20. Drapkin R, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65:2162-9. (Pubitemid 40490123)
21. Havrilesky LJ, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008; 110:374-82.
22. Hellstrom I, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63:3695-700.
23. Huhtinen K, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100:1315-9.
24. Moore RG, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112:40-6.
25. Montagnana M, et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 2009; 23:331-5.
26. Shah CA, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4 and CA125. Cancer Epidemiol Biomarkers Prev 2009; 18:1365-72.
27. Hellstrom I, Hellstrom KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol 2008; 622:15-21.
28. Li J, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 2009; 9:555-66.
29. Kim JH, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287:1671-9.
30. Nakae M, et al. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res 2006; 32:309-14. (Pubitemid 43800424)
31. Kim K, et al. Development and validation of a protein-based signature for the detection of ovarian cancer. Clin Lab Med 2009; 29:47-55.
32. Visintin I, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008; 14:1065-72.
33. Johnston NI, et al. Osteopontin as a target for cancer therapy. Front Biosci 2008; 13:4361-72.
34. Rosen DG, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005; 99:267-77.
35. Shigemasa K, et al. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncol Rep 2004; 11:1153-9.
36. Borgono CA, et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 2003; 63:9032-41.
37. Bandiera E, et al. Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. Int J Gynecol Cancer 2009; 19:1015-21.
38. White NM, et al. Human kallikrein related peptidases 6 and 13 in combination with CA125 is a more sensitive test for ovarian cancer than CA125 alone. Cancer Biomark 2009; 5:279-87.
39. Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem 2008; 54:1600-7.
40. Sobel G, et al. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma. Gynecol Oncol 2006; 103:591-8. (Pubitemid 44740102)
41. Sobel G, et al. Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma. Hum Pathol 2005; 36:162-9. (Pubitemid 40320530)
42. Sobel G, et al. Changes of cell adhesion and extracellular matrix (ECM) components in cervical intraepithelial neoplasia. Pathol Oncol Res 2005; 11:26-31. (Pubitemid 40646272)
43. Kleinberg L, et al. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol 2008; 39:747-57. (Pubitemid 351618309)
44. Morin PJ, Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005; 65:9603-6.
45. Choi YL, et al. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol Histopathol 2007; 22:1185-95.
46. Huang YH, et al. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc Natl Acad Sci USA 2009; 106:3426-30.
47. Szabo I, et al. Claudins as diagnostic and prognostic markers in gynecological cancer. Histol Histopathol 2009; 24:1607-15.
48. Kuk C, et al. Nidogen-2: A new serum biomarker for ovarian cancer. Clin Biochem 2009.
49. Basal E, et al. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One 2009; 4:6292.
50. Lorenzi PL, Weinstein JN. Asparagine synthetase: a new potential biomarker in ovarian cancer. Drug News Perspect 2009; 22:61-4.
51. Taylor DD, Gercel-Taylor C, Parker LP. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 2009; 115:112-20.
52. Balch C, et al. Minireview: epigenetic changes in ovarian cancer. Endocrinology 2009; 150:4003-11.
53. Baldwin RL, et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 2000; 60:5329-33.
54. Volinia S, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103:2257-61.
55. Dahiya N, et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008; 3:2436.
56. Shell S, et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 2007; 104:11400-5.
57. Yang N, et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008; 68:10307-14.
58. Hu X, et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 2009; 114:457-64.
59. Nam EJ, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008; 14:2690-5.
60. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110:13-21.
61. Lodes MJ, et al. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009; 4:6229.
62. Helou K, et al. Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors. Cancer Genet Cytogenet 2006; 170:1-8.
63. Dimova I, et al. Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array CGH analysis. Tumori 2009; 95:357-66.
64. Bruchim I, et al. Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma. Cancer Genet Cytogenet 2009; 190:66-70.
65. Petricoin EF, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-7.
66. Lopez MF, et al. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem 2007; 53:1067-74.
67. Wu SP, et al. SELDI-TOF MS profiling of plasma proteins in ovarian cancer. Taiwan J Obstet Gynecol 2006; 45:26-32.
68. Petri AL, et al. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet Gynecol Scand 2009; 88:18-26.
69. Gunawardana CG, et al. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. J Proteome Res 2009; 8:4705-13.
70. Timmerman D, et al. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model. Am J Obstet Gynecol 1999; 181:57-65.
71. Ferrazzi E, et al. Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study. Ultrasound Obstet Gynecol 1997; 10:192-7.
72. Mol BW, et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Gynecol Oncol 2001; 80:162-7.
73. Ueland FR, et al. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecol Oncol 2003; 91:46-50.
74. DePriest PD, et al. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 1993; 51:7-11.
75. Fleischer AC, et al. Quantified color Doppler sonography of tumor vascularity in an animal model. J Ultrasound Med 1999; 18:547-51.
76. Donnelly EF, et al. Quantified power Doppler US of tumor blood flow correlates with microscopic quantification of tumor blood vessels. Radiology 2001; 219:166-70.
77. Fleischer AC, et al. Sonographic depiction of microvessel perfusion: principles and potential. J Ultrasound Med 2004; 23:1499-506.
78. Fleischer AC. Sonographic depiction of tumor vascularity and flow: from in vivo models to clinical applications. J Ultrasound Med 2000; 19:55-61.
79. Cohen LS, et al. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 2001; 82:40-8.
80. Fishman DA, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol 2005; 192:1214-21.
81. van Nagell JR Jr, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000; 77:350-6.
82. Ferrara KW, et al. Evaluation of tumor angiogenesis with US: imaging, Doppler and contrast agents. Acad Radiol 2000; 7:824-39.
83. Orden MR, Jurvelin JS, Kirkinen PP. Kinetics of a US contrast agent in benign and malignant adnexal tumors. Radiology 2003; 226:405-10.
84. Brasch R, Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol 2000; 34:148-55.
85. Fleischer AC, et al. Contrast-enhanced transvaginal sonography of benign versus malignant ovarian masses: preliminary findings. J Ultrasound Med 2008; 27:1011-8.
86. Fleischer AC, et al. Diagnostic parameters to differentiate benign from malignant ovarian masses with contrast-enhanced transvaginal sonography. J Ultrasound Med 2009; 28:1273-80.
87. Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
88. Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50.
89. Miller K, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76.
90. Burger RA, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:5165-71.
91. Cannistra SA, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25:5180-6.
92. Garcia AA, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26:76-82.
93. Han ES, Monk BJ. Bevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther 2007; 7:1339-45.
94. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007; 105:3-6.
95. Matulonis UA, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube and peritoneal cancer. J Clin Oncol 2009; 27:5601-6.
96. Holash J, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99:11393-8.
97. Sanchez-Munoz A, et al. Current status of anti-angiogenic agents in the treatment of ovarian carcinoma. Clin Transl Oncol 2009; 11:589-95.
98. Han ES, Lin P, Wakabayashi M. Current status on biologic therapies in the treatment of epithelial ovarian cancer. Curr Treat Options Oncol 2009; 10:54-66.
99. Ciardiello F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol 2005; 1:221-34.
100. Salomon DS, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
101. Gordon AN, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005; 15:785-92.
102. Schilder RJ, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005; 11:5539-48.
103. Wagner U, et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy - a phase II trial of the AGO Ovarian Cancer Study Group (AGOOVAR 2.6). Gynecol Oncol 2007; 105:132-7.
104. Posadas EM, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007; 109:1323-30.
105. Secord AA, et al. Phase II trial of cetuximab and carbo-platin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol 2008; 108:493-9.
106. Konner J, et al. A phase II study of cetuximab/paclitaxel/ carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal or fallopian tube cancer. Gynecol Oncol 2008; 110:140-5.
107. McPhillips F, et al. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis 2006; 27:729-39.
108. McPhillips F, et al. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br J Cancer 2001; 85:1753-8. (Pubitemid 34081523)
109. Lee JM, et al. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer.
110. Altomare DA, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004; 23:5853-7.
111. Cheng JQ, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992; 89:9267-71.
112. Jung YJ, et al. IL-1beta-mediated upregulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003; 17:2115-7.
113. Huang S, et al. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000; 60:5334-9.
114. Mabuchi S, et al. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 2004; 279:23477-85.
115. Liu GH, et al. Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int J Gynecol Cancer 2006; 16:1777-82.